Suzhou Novartis Technical Development Co., Ltd.
Records under this name other than patents Suzhou Novartis Technical Development Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Suzhou Novartis Technical Development Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,878,973 | Bicyclic Compounds and their Uses conveyed to Novartis AG In force · High confidence | In force | High confidence | |
| US 12,679,834 | 7-oxo-[1,2,4]triazolo[1,5-a]pyrimidin-4(7H)-yl) Compounds and Uses Thereof conveyed to Novartis AG In force · High confidence | In force | High confidence | |
| US 12,441,737 | Manufacture of Compounds and Compositions for Inhibiting the Activity of SHP2 conveyed to Novartis AG In force · High confidence | In force | High confidence | |
| US 12,084,442 | Naphthyridinone Derivatives for the Treatment of a Disease or Disorder now held by Novartis AG In force · High confidence | In force | High confidence | |
| US 12,774,275 | Compounds and Compositions for the Treatment of Coronaviral Related Diseases conveyed to Novartis AG In force · High confidence | In force | High confidence | |
| US 12,378,222 | NLRP3 Inflammasome Inhibitors now held by Novartis AG In force · High confidence | In force | High confidence | |
| 18/002,291 | Process for the Manufacture of 1,4-Disubstituted Pyridazine Compounds conveyed to Novartis AG Abandoned Abandoned May 14, 2024 | Abandoned | Abandoned May 14, 2024 | |
| 18/250,466 | New Crystalline Forms of a Kras G12C Inhibitor Compound conveyed to Novartis AG Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/281,732 | Fatty Acid-Bifunctional Degrader Conjugates and Their Methods of Use conveyed to Novartis AG Abandoned Abandoned Nov 17, 2026 | Abandoned | Abandoned Nov 17, 2026 | |
| 18/363,207 | NLRP3 Inflammasome Inhibitors conveyed to Novartis AG Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |